JPRN-jRCT2051230076招募中1 期
A Phase 1, Randomized, Double-blind, Multi-center, Placebo-controlled Trial to Evaluate the Safety and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent VLP Vaccine in Healthy Japanese Infants 5 Months of Age at First Trial Vaccine Administration
Takahashi Kazuma0 个研究点目标入组 21 人开始时间: 2023年7月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 4month 2weeks old 至 <= 5month 2weeks old（—）
- 性别
- All
入选标准
- •Male or female subject aged 5 months (-14/+14 days).
- •Infants who are in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and clinical judgment of the investigator.
- •The subjects legally acceptable representative (LAR) signs and dates a written, informed consent form (ICF) and any required privacy authorization prior to the initiation of any trial procedures, after the nature of the trial has been explained according to local regulatory requirements.
- •The subjects LAR is willing and able to comply with trial procedures and is available for the duration of follow-up.
排除标准
- •Clinically significant abnormality in growth by length/height, weight, or head circumference (according to national guidelines).
- •Gastrointestinal abnormalities or any chronic gastrointestinal disease, including any uncorrected congenital malformation of the gastrointestinal tract according to medical history and/or physical examination.
- •Chronic use of oral corticosteroids (equivalent to 20 mg/day prednisolone for >=12 weeks / >=2 mg/kg body weight /day for >=2 weeks) within 60 days prior to Visit 1 (use of inhaled, intranasal, or topical corticosteroids is allowed).
- •Use of parenteral corticosteroids (equivalent to 20 mg/day prednisolone for >=12 weeks / >=2 mg/kg body weight /day for >=2 weeks. Use of inhaled, intranasal or topical corticosteroid is allowed) within 60 days prior to Visit 1.
- •Receipt of immunostimulants within 60 days prior to Visit 1.
- •Receipt of parenteral, epidural or intra-articular immunoglobulin (Ig) preparations, blood products, and/or plasma derivatives within 90 days prior to Visit 1 or planned during the full duration of the trial.
- •Receipt of immunosuppressive therapy prior to Visit 1.
- •Known hypersensitivity or allergy to any of the trial vaccine components (including excipients).
- •Any clinically significant active infection (as assessed by the investigator) or temperature >= 38.0 C (>100.4 F), regardless of method used, within 3 days prior to intended trial vaccine administration.
- •Gastroenteritis within 7 days before planned dosing (can warrant delay of trial vaccine administration).
- •History of, e.g., convulsions/febrile convulsions, or any illness, that, in the opinion of the investigator, might interfere with the results of the trial or pose additional risk to the subjects due to participation in the trial.
- •Abnormalities of splenic or thymic function.
- •Known or suspected impairment/alteration of immune function.
- •Known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
- •Receipt or scheduled receipt of any other approved or authorized vaccines within 14 days (for all non-live vaccines or oral live vaccines) or 28 days (for parenteral live vaccines) before or after trial vaccine administration.
- •Participation in any clinical trial with another investigational product 30 days prior to first trial visit or intention to participate in another clinical trial at any time during the conduct of this trial.
- •Seropositive for, or in evaluation for, possible human immunodeficiency virus infection.
- •Hepatitis B or C infection.
- •Any heritable immunodeficiency or autoimmune disease.
- •Subjects LAR or subjects first-degree relatives involved in the trial conduct.
研究者
相似试验
已完成
1 期
Intranasal Adenoviral vector COVID-19 vaccine (BBV154) Phase 1 studyCTRI/2021/02/031295Bharat Biotech International Ltd
终止
1 期
A Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Topical SM04755 Solution Following Topical Administration to Subjects with Mild to Moderate Plaque PsoriasisPlaque psoriasisACTRN12617001178336Samumed Pacific Pty Ltd13
尚未招募
1 期
A Study to Evaluate BW-00163 in Subjects with HypertensioHypertensionACTRN12622001430729ARGO BIOPHARMA AUSTRALIA PTY LTD48
已完成
不适用
A Phase 1 Clinical study, Safety, Tolerability and PK of SP-8203Diseases of the nervous systemKCT0001742Shin Poong Pharm72
进行中（未招募）
不适用
A Randomized, Multicenter, Double Blinded, Phase IV Study Comparing the Safety and Efficacy of Pegasys 180 µg plus Copegus 1000 or 1200 mg to the Currently Approved Combination of Pegasys 180 µg plus Copegus 800 mg in Interferon-naïve Patients with Chronic Hepatitis C Genotype 1 virus infection coinfected with human immunodeficiency virus (HIV-1).Patients with chronic hepatitis C (CHC) genotype 1 virus coinfected with human immunodeficiency virus type 1 (HIV-1)EUCTR2005-005506-23-PTF. Hoffmann-La Roche Ltd400